Genmab scraps development of experimental cancer therapy [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
The ?company had assumed sole responsibility for the development and potential commercialization of ?acasunlimab in 2024, after BioNTech opted not to continue studying the therapy. Acasunlimab is a bispecific antibody designed to produce an anti-tumor response by activating a receptor called 4-1BB on T ?cells and natural killer ?cells. It was in late-stage development for solid tumors, including metastatic non-small cell lung cancer. "Although the ?data have been encouraging, the compelling opportunities we see in our late-stage pipeline led us to focus our investments where we believe ?we can deliver the greatest benefit for patients and ?shareholders," said CEO Jan van de Winkel. Genmab will concentrate resources on programs including cancer therapies Epkinly, petosemtamab and rinatabart sesutecan, which are also in late-stage development. The company gained access to petosemtamab through its $8 billion buyout of Dutch cancer drugmaker ?Merus in September. The drug is ?be
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab Portfolio Prioritization Update [Yahoo! Finance]Yahoo! Finance
- Genmab Portfolio Prioritization UpdateBusiness Wire
- Genmab Portfolio Prioritization UpdateGlobeNewswire
- Does Genmab's 2025 Rally Match Its DCF and Earnings Valuation Outlook? [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period [Yahoo! Finance]Yahoo! Finance